#United States #FDA Approval #Princeton #CytoSorbents #DrugSorb-ATR

CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results

CytoSorbents Corporation, a key player in blood purification for critical care, shared its financial results for the fourth quarter and full year ending December 31, 2024. The company reported a 35.6 million dollars in product sales for the year, achieving a 25% increase in Q4 sales when compared to the previous year. The growth reflects the successful execution of their strategic initiatives and robust commercial performance. Notably, product gross margins also improved to an impressive 71%, compared to 68% in the previous quarter.

Dr. Phillip Chan, the CEO of CytoSorbents, expressed optimism, noting their performance in delivering critical healthcare solutions and the solid financial position attained through effective cash management and cost-cutting strategies. The company has focused on expanding its market access for its DrugSorb-ATR product, which is anticipated to receive critical regulatory approvals from both the FDA and Health Canada in 2025

Innovative Approach to Blood Purification

The company is renowned for its groundbreaking technology that addresses life-threatening conditions by effectively purging harmful substances from blood during critical procedures. Its flagship product, CytoSorb, has made substantial headway in the European market and is being prepared for potential use in North America.

In 2024, the organization endeavored to maximize regulatory momentum, achieving significant milestones with its DrugSorb-ATR therapy aimed at minimizing perioperative bleeding complications in patients undergoing certain surgeries. The acceptance of the De Novo application by the FDA marked a pivotal moment for the company as they seek to obtain marketing approval.

Financial Highlights and Strategic Moves

CytoSorbents demonstrated a resilient financial performance, illustrated as follows:

• - Product Revenue hit 9.2 million dollars in Q4, climbing from 7.3 million dollars in Q4 2023.
• - Largely due to increased revenues and 30% reduction in operational expenses, operating loss improved by 61%.
• - Net loss reported at 7.6 million dollars, slightly deteriorated from 6.1 million dollars in the same quarter of the previous year, reflecting ongoing investment into product development and marketing efforts.

The company attributed its robust fourth-quarter results to a successful Rights Offering, which raised 7.3 million dollars. The proceeds have bolstered CytoSorbents' balance sheet significantly, enhancing liquidity to approximately 17.0 million dollars.

Navigating Challenges in Key Markets

Despite the positive trajectory, CytoSorbents faces challenges, particularly in its primary market of Germany, where sales growth stalled for two consecutive years. To counteract this stagnation, a comprehensive reorganization of the direct sales team has been implemented. This includes a complete rebalancing of sales territories and accounts aimed at reinvigorating sales growth and fostering deeper customer engagement.

Dr. Chan acknowledged the short-term disturbances that may arise from these strategic changes but remained confident that these actions would cultivate a healthier growth trajectory in the second half of the fiscal year.

Future Outlook

Looking ahead, CytoSorbents is straddling opportunities both in the North American market and beyond. With promising data supporting the efficacy of DrugSorb-ATR, they anticipate a sizable market potential exceeding 1 billion dollars as they diversify into other blood thinners and surgical applications.

The company's commitment to leveraging clinical data to bolster product adoption is paramount, with significant presentations scheduled at major cardiovascular conferences throughout the year. These events are poised to highlight the clinical benefits of their innovative solutions, reinforcing CytoSorbents' role as a leader in blood purification technologies.

In summary, 2024 has been marked by promising financial results, strategic improvements, and a commitment to addressing critical healthcare challenges. With the groundwork laid for upcoming regulatory approvals and effective market entry strategies, CytoSorbents Corporation is strategically positioning itself for growth and enhanced shareholder value.